Latest Astellas Pharma US Inc. Stories

DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of overactive bladder (OAB) (Yes: 7, No: 4, Abstain: 1). Today's committee recommendation, although not...

DEERFIELD, Ill., March 13, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. (Astellas), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) today announced the debut of the Astellas Oncology Cycling Team presented by Athletes By Design (ABD) Cycling. The team is registered as a Domestic Elite Team with USA Cycling and will concentrate on the development of young, up-and-coming riders. The team will compete in the National Criterium Calendar, National Racing Calendar,...

DEERFIELD, Ill., Sept. 23, 2011 /PRNewswire/ -- More than 500 employees from Astellas Pharma US, Inc. (Astellas Pharma US), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Astellas) will fan out from company headquarters in Deerfield on Friday, Sept. 23, to tackle seven service projects in the City of Chicago and Lake County as part of the pharmaceutical company's annual Changing Tomorrow Day corporate service commitment. They join more than 600 other Astellas employees who have...

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds. "Astellas has made significant...

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

STAINES, England, April 11, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today announced the appointment of Ken Jones as its President and CEO. Mr Jones, who since July 2007 has held the position of COO at Astellas Pharma Europe Ltd., succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc., the U.S. subsidiary of...

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

TOKYO, Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that Donald B. Rice, PhD. will retire from Astellas Pharma Inc.'s affiliate Agensys, Inc. ("Agensys"). Sef Kurstjens, M.D., PhD. has been appointed the new Chief Executive Officer and President. Dr. Rice founded Agensys, Inc. (formerly UroGenesys, Inc.) in 1996. The company, located in Santa Monica, CA, USA, was acquired by Astellas in December, 2007....

CHICAGO and DEERFIELD, Ill., Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a research-based pharmaceutical company based in Deerfield, Ill., is pleased to donate 150 used laptops to Midtown Educational Foundation, a nonprofit academic enrichment organization that serves over 1,000 students and parents in need each year through its Chicago-based Metro Achievement Center for girls and Midtown Center for boys. "The Midtown Educational Foundation is thrilled to partner...

CHICAGO and DEERFIELD, Ill., Oct. 28 /PRNewswire/ -- A new national survey released today shows large percentages of science teachers and parents strongly agree that demonstrating real-life applications in science (87 percent and 72 percent, respectively) can help make science education more interesting for U.S. students. Almost all science teachers (99 percent) and nine in ten parents (90 percent) feel that science education is important, if not very important for a child's future, but...